PMID- 31900869
OWN - NLM
STAT- MEDLINE
DCOM- 20210128
LR  - 20210128
IS  - 1613-2246 (Electronic)
IS  - 0021-5155 (Linking)
VI  - 64
IP  - 2
DP  - 2020 Mar
TI  - The effects of intravitreal triamcinolone acetonide in diabetic macular edema 
      refractory to anti-VEGF treatment.
PG  - 196-202
LID - 10.1007/s10384-019-00710-6 [doi]
AB  - PURPOSE: To investigate the efficacy and safety of primary intravitreal 
      triamcinolone acetonide (IVTA) in eyes affected by diabetic macular edema (DME) 
      refractory to anti-vascular endothelial growth factor (VEGF) therapy. STUDY 
      DESIGN: Retrospective observational study METHODS: The medical records of 
      patients who attended our clinic from March 2013 to September 2018 with 
      refractory macular were reviewed. We included the patients who were injected at 
      least one IVTA and completed 6 months of observation. Best-corrected Snellen 
      visual acuity (VA), central macular thickness (CMT), intraocular pressure (IOP), 
      and adverse events (AEs) were examined at baseline and at 1 month, 2 months, 3 
      months, and 6 months. RESULTS: Sixty-four eyes of 54 subjects were included. The 
      mean VA was improved significantly at all time points compared to pre-treatment 
      (P < 0.0001), with the greatest mean improvement at 1 month (0.3 logMAR). The 
      reduction in mean CMT was also significant at all follow-up examinations compared 
      to baseline (P < 0.0001), with the greatest decrease at 1 month (113.68 +/- 53.78 
      mum). A poorer VA before injection was a factor that influenced visual gain 1 
      month post treatment (0.247 logMAR units/unit increase in baseline VA, P = 
      0.006). The most common AE associated with IVTA treatment was elevated IOP (11 
      eyes), observed significantly more often after IVTA injections containing a 
      preservative (25.8%) than after those that were preservative-free (9.1%) (P = 
      0.033). CONCLUSION: IVTA injection can be an alternative steroid treatment for 
      DME refractory to anti-VEGF therapy.
FAU - Hong, In Hwan
AU  - Hong IH
AD  - Department of Ophthalmology, Dongtan Sacred Heart Hospital, Hallym University 
      Medical Center, Hwaseong-si, Gyeonggi-do, Korea.
FAU - Choi, Wonseok
AU  - Choi W
AD  - Department of Ophthalmology, Dongtan Sacred Heart Hospital, Hallym University 
      Medical Center, Hwaseong-si, Gyeonggi-do, Korea.
FAU - Han, Jae Ryong
AU  - Han JR
AD  - Department of Ophthalmology, Dongtan Sacred Heart Hospital, Hallym University 
      Medical Center, Hwaseong-si, Gyeonggi-do, Korea. scarpel@hallym.or.kr.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20200103
PL  - Japan
TA  - Jpn J Ophthalmol
JT  - Japanese journal of ophthalmology
JID - 0044652
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Glucocorticoids)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - F446C597KA (Triamcinolone Acetonide)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Angiogenesis Inhibitors/*administration & dosage
MH  - Bevacizumab/administration & dosage
MH  - Diabetic Retinopathy/complications/diagnosis/*drug therapy
MH  - Female
MH  - Glucocorticoids/administration & dosage
MH  - Humans
MH  - Intraocular Pressure
MH  - Intravitreal Injections
MH  - Macula Lutea/drug effects/*pathology
MH  - Macular Edema/diagnosis/*drug therapy/etiology
MH  - Male
MH  - Middle Aged
MH  - Ranibizumab/administration & dosage
MH  - Retrospective Studies
MH  - Tomography, Optical Coherence/methods
MH  - Treatment Outcome
MH  - Triamcinolone Acetonide/*administration & dosage
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors
MH  - *Visual Acuity
OTO - NOTNLM
OT  - Diabetic macular edema
OT  - IVTA
OT  - Refractory DME
EDAT- 2020/01/05 06:00
MHDA- 2021/01/29 06:00
CRDT- 2020/01/05 06:00
PHST- 2019/02/24 00:00 [received]
PHST- 2019/11/21 00:00 [accepted]
PHST- 2020/01/05 06:00 [pubmed]
PHST- 2021/01/29 06:00 [medline]
PHST- 2020/01/05 06:00 [entrez]
AID - 10.1007/s10384-019-00710-6 [pii]
AID - 10.1007/s10384-019-00710-6 [doi]
PST - ppublish
SO  - Jpn J Ophthalmol. 2020 Mar;64(2):196-202. doi: 10.1007/s10384-019-00710-6. Epub 
      2020 Jan 3.